Evaluation of N-[C-11]Methyl-AMD3465 as a PET Tracer for Imaging of CXCR4 Receptor Expression in a C6 Glioma Tumor ModelHartimath, S. V., van Waarde, A., Dierckx, R. A. J. O. & de Vries, E. F. J., Nov-2014, In : Molecular pharmaceutics. 11, 11, p. 3810-3817 8 p.
Research output: Contribution to journal › Article › Academic › peer-review
The chemokine receptor CXCR4 and its ligand CXCL12 play an important role in tumor progression and metastasis. CXCR4 receptors are expressed by many cancer types and provide a potential target for treatment. Noninvasive detection of CXCR4 may aid diagnosis and improve therapy selection. It has been demonstrated in preclinical studies that positron emission tomography (PET) with a radiolabeled small molecule could enable noninvasive monitoring of CXCR4 expression. Here, we prepared N-[C-11]methyl-AMD3465 as a new PET tracer for CXCR4. N-[C-11]Methyl-AMD3465 was readily prepared by N-methylation with [C-11]CH3OTf. The tracer was obtained in a 60 +/- 2% yield (decay corrected), the purity of the tracer was >99%, and specific activity was 47 +/- 14 GBq/mu mol. Tracer stability was tested in vitro using liver microsomes and rat plasma; excellent stability was observed. The tracer was evaluated in rat C6 glioma and human PC-3 cell lines. In vitro cellular uptake of N-[C-11]methyl-AMD3465 was receptor mediated. The effect of transition metal ions (Cu2+, Ni2+, and Zn2+) on cellular binding was examined in C6 cells, and the presence of these ions increased the cellular binding of the tracer 9-, 7-, and 3-fold, respectively. Ex vivo biodistribution and PET imaging of N-[C-11]methyl-AMD3465 were performed in rats with C6 tumor xenografts. Both PET and biodistribution studies demonstrated specific accumulation of the tracer in the tumor (SUV 0.6 +/- 0.2) and other CXCR4 expressing organs, such as lymph node (1.5 +/- 0.2), liver (8.9 +/- 1.0), bone marrow (1.0 +/- 0.3), and spleen (1.0 +/- 0.1). Tumor uptake was significantly reduced (66%, p <0.01) after pretreatment with Plerixafor (AMD3100). Biodistribution data indicates a tumor-to-muscle ratio of 7.85 and tumor-to-plasma ratio of 1.14, at 60 min after tracer injection. Our data demonstrated that N-[C-11]methyl-AMD3465 is capable of detecting physiologic CXCR4 expression in tumors and other CXCR4 expressing tissues. These results warrant further evaluation of N-[C-11]methyl-AMD3465 as a potential PET tracer for CXCR4 receptor imaging.
|Number of pages||8|
|Publication status||Published - Nov-2014|
- chemokine receptor 4, tumor imaging, PET, AMD3465, cancer and metastasis, radiotracer, HUMAN CANCER XENOGRAFTS, CHEMOKINE RECEPTOR, BREAST-CANCER, ANTAGONIST, CELLS, MICROENVIRONMENT, METASTASIS, INHIBITION, MONOCYCLAM, BICYCLAM